Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes.

Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.


Articles from the journal in Current Drug Targets , 17 Issue 9

  • From “An Enzyme Able to Destroy Penicillin” to Carbapenemases: 70 Years of Beta-lactamase Misbehaviour
  • Decoding the Structural Basis For Carbapenem Hydrolysis By Class A β-lactamases: Fishing For A Pharmacophore
  • Structural and Functional Aspects of Class A Carbapenemases
  • B1-Metallo-β-Lactamases: Where Do We Stand?
  • Structural and Functional Aspects of Extended-Spectrum AmpC Cephalosporinases
  • Structure-Function Relationships of Class D Carbapenemases
  • Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies – The State of the Art
  • MicroRNAs in Breast Cancer: One More Turn in Regulation

For details on the articles, please visit this link ::